Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Hypogonadism is the most common morbidity in patients with transfusion-dependent anemias such as thalassemia major. We used magnetic resonance imaging (MRI) to measure pituitary R2 (iron) and volume to determine at what age these patients develop pituitary iron overload and volume loss. We recruited 56 patients (47 with thalassemia major, five with chronically transfused thalassemia intermedia and four with Blackfan-Diamond syndrome) to have pituitary MRIs to measure pituitary R2 and volume. Hypogonadism was defined clinically based on the timing of secondary sexual characteristics or the need for sex hormone replacement therapy. Patients with transfusional iron overload begin to develop pituitary iron overload in the first decade of life; however, clinically significant volume loss was not observed until the second decade of life. Severe pituitary iron deposition (Z > 5) and volume loss (Z < -2.5) were independently predictive of hypogonadism. Pituitary R2 correlated significantly with serum ferritin as well as liver, pancreatic, and cardiac iron deposition by MRI. Log pancreas R2* was the best single predictor for pituitary iron, with an area under the receiving operator characteristic curve of 0.88, but log cardiac R2* and ferritin were retained on multivariate regression with a combined r(2) of 0.71. Pituitary iron overload and volume loss were independently predictive of hypogonadism. Many patients with moderate-to-severe pituitary iron overload retained normal gland volume and function, representing a potential therapeutic window. The subset of hypogonadal patients having preserved gland volumes may also explain improvements in pituitary function observed following intensive chelation therapy.
Department of Pediatrics, Division of Cardiology, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Leila J
LJ
Noetzli
Ashok
A
Panigrahy
Steven D
SD
Mittelman
Aleya
A
Hyderi
Ani
A
Dongelyan
Thomas D
TD
Coates
John C
JC
Wood
D000293:Adolescent; D000328:Adult; D029503:Anemia, Diamond-Blackfan / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015913:Chelation Therapy; D002648:Child; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007006:Hypogonadism / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D007501:Iron / Q000378:metabolism*; D019190:Iron Overload / Q000150:complications / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009929:Organ Size; D010179:Pancreas / Q000378:metabolism / Q000473:pathology; D010902:Pituitary Gland / Q000378:metabolism* / Q000473:pathology; D013997:Time Factors; D065227:Transfusion Reaction; D017086:beta-Thalassemia / Q000378:metabolism* / Q000473:pathology / Q000628:therapy
D005293:Ferritins; D007501:Iron